Evidence map›Paper›PMID 41966805›Full record

ArticleBiomedicine & pharmacotherapy = Biomedecine & pharmacotherapie2026

A novel colchicine-binding site inhibitor suppresses triple-negative breast cancer growth and metastasis and synergizes with anti-PD-L1 immunotherapy in an immunogenic cancer model.

Kelli L Adeleye, Damilola Oluwalana, Raisa Krutilina, Yang Xie, Satyanarayana Pochampally, Lily Waltz, Gustavo A Miranda-Carboni, Duane D Miller, Tiffany N Seagroves, Wei Li

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Kelli L AdeleyeDepartment of Pharmaceutical Sciences, College of Pharmacy, University of Tennessee Health Science Center, Memphis, TN 38163, United States.
Damilola OluwalanaDepartment of Pharmacy and Pharmaceutical Sciences, St. Jude Children's Research Hospital, Memphis, TN 38105, United States; Department of Pathology, College of Medicine, University of Tennessee Health Science Center, Memphis, TN 38163, United States.
Raisa KrutilinaDepartment of Pathology, College of Medicine, University of Tennessee Health Science Center, Memphis, TN 38163, United States; John W. Deming Department of Medicine and Tulane Cancer Center, School of Medicine, Tulane University, New Orleans, LA 70112, United States.
Yang XieDepartment of Pharmaceutical Sciences, College of Pharmacy, University of Tennessee Health Science Center, Memphis, TN 38163, United States.
Satyanarayana PochampallyDepartment of Pharmaceutical Sciences, College of Pharmacy, University of Tennessee Health Science Center, Memphis, TN 38163, United States.
Lily WaltzDepartment of Pharmaceutical Sciences, College of Pharmacy, University of Tennessee Health Science Center, Memphis, TN 38163, United States.
Gustavo A Miranda-CarboniDepartment of Medicine, College of Medicine, University of Tennessee Health Science Center, Memphis, TN 38163, United States.
Duane D MillerDepartment of Pharmaceutical Sciences, College of Pharmacy, University of Tennessee Health Science Center, Memphis, TN 38163, United States.
Tiffany N SeagrovesDepartment of Pathology, College of Medicine, University of Tennessee Health Science Center, Memphis, TN 38163, United States; John W. Deming Department of Medicine and Tulane Cancer Center, School of Medicine, Tulane University, New Orleans, LA 70112, United States.
Wei LiDepartment of Pharmaceutical Sciences, College of Pharmacy, University of Tennessee Health Science Center, Memphis, TN 38163, United States. Electronic address: wli@uthsc.edu.

Funding

Targeting the colchicine site in tubulin for advanced melanomaR01CA148706 · NCI · UNIVERSITY OF TENNESSEE HEALTH SCI CTR · PI LI, WEI, MILLER, DUANE D · 2011 to 2025
$5.3M
Targeting brain and bone metastases in metastatic breast cancer for improved patient survivalR01CA276152 · NCI · UNIVERSITY OF TENNESSEE HEALTH SCI CTR · PI WEI LI, Tiffany Nicole Seagroves · 2023 to 2026
$2.4M
NCI NIH HHS R01 CA148706NCI NIH HHS R01 CA276152
6 · The paper itself

Abstract

Triple-negative breast cancer (TNBC) accounts for approximately 15% of all breast cancer cases and is defined by the absence of estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 (HER2) expression. Approximately 40% of patients with TNBC develop metastatic disease, reducing median survival to 13.3 months. Paclitaxel remains a standard chemotherapeutic option; however, its efficacy is often limited by ATP-driven efflux pumps and βIII-tubulin overexpression. These limitations underscore the need for agents that can overcome resistance and suppress metastasis. Colchicine-binding site inhibitors (CBSIs) target the colchicine-binding site on tubulin to induce G

Indexed as

B7-H1 AntigenColchicineImmune Checkpoint InhibitorsImmunotherapyTriple Negative Breast NeoplasmsAnimalsBinding SitesCell Line, TumorCell ProliferationDrug SynergismFemaleHumansMiceMice, NudeNeoplasm MetastasisTubulin ModulatorsB7-H1 AntigenCD274 protein, humanColchicineImmune Checkpoint InhibitorsTubulin ModulatorsBreast cancerImmune checkpoint inhibitorMetastasisTubulin inhibitor

Identifiers

PMID41966805
PMCPMC13225900

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.